4th Quarter - Amendment

BLUEBIRD BIO, INC. for BLUEBIRD BIO, INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$140,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 16, 2024 $140,000 Replaced
4th Quarter - Amendment (this page) Apr 3, 2024 $140,000 Replaced
4th Quarter - Amendment Apr 4, 2024 $140,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR 2666 - MVP Act Medicaid Program: Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program (CMS-2434-P) CMMI sought bluebird input on potential gene therapy demo for sickle cell disease beneficiaries of Medicaid

LobbyistCovered position, as disclosed
CHRISTINA HARTMAN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 2666 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.